B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics

I. Torres-Courchoud, Horng Haur Chen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.

Original languageEnglish (US)
JournalRevista Clinica Espanola
DOIs
StateAccepted/In press - Jan 11 2016

Fingerprint

Brain Natriuretic Peptide
Atrial Natriuretic Factor
Homeostasis
Heart Failure
Biomarkers
C-Type Natriuretic Peptide
Kidney
Phase III Clinical Trials
Natriuretic Peptides
Therapeutics
Hemostasis
Japan
Peptides
Pharmaceutical Preparations
Ularitide

Keywords

  • Brain natriuretic peptide
  • Heart failure
  • Natriuretic peptide
  • Recombinant natriuretic peptides
  • Volume homeostasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

B-type natriuretic peptide and acute heart failure : Fluid homeostasis, biomarker and therapeutics. / Torres-Courchoud, I.; Chen, Horng Haur.

In: Revista Clinica Espanola, 11.01.2016.

Research output: Contribution to journalArticle

@article{15a5a7ff87bd4969bd15b1e1734877e2,
title = "B-type natriuretic peptide and acute heart failure: Fluid homeostasis, biomarker and therapeutics",
abstract = "Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.",
keywords = "Brain natriuretic peptide, Heart failure, Natriuretic peptide, Recombinant natriuretic peptides, Volume homeostasis",
author = "I. Torres-Courchoud and Chen, {Horng Haur}",
year = "2016",
month = "1",
day = "11",
doi = "10.1016/j.rce.2016.01.009",
language = "English (US)",
journal = "Revista Clinica Espanola",
issn = "0014-2565",
publisher = "Elsevier Espana",

}

TY - JOUR

T1 - B-type natriuretic peptide and acute heart failure

T2 - Fluid homeostasis, biomarker and therapeutics

AU - Torres-Courchoud, I.

AU - Chen, Horng Haur

PY - 2016/1/11

Y1 - 2016/1/11

N2 - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.

AB - Natriuretic peptides are a family of peptides with similar structures, but are genetically distinct with diverse actions in cardiovascular, renal and fluid homeostasis. The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney. Nesiritide, a human recombinant BNP, was approved by the Federal Drug Administration (FDA) for the management of acute heart failure (AHF) in 2001. Human recombinant ANP (Carperitide) was approved for the same clinical indication in Japan in 1995, and human recombinant Urodilatin (Ularitide) is currently undergoing phase III clinical trial (TRUE AHF). This review will provide an update on important issues regarding the role of BNP in fluid hemostasis as a biomarker and therapeutics in AHF.

KW - Brain natriuretic peptide

KW - Heart failure

KW - Natriuretic peptide

KW - Recombinant natriuretic peptides

KW - Volume homeostasis

UR - http://www.scopus.com/inward/record.url?scp=84959511118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959511118&partnerID=8YFLogxK

U2 - 10.1016/j.rce.2016.01.009

DO - 10.1016/j.rce.2016.01.009

M3 - Article

AN - SCOPUS:84959511118

JO - Revista Clinica Espanola

JF - Revista Clinica Espanola

SN - 0014-2565

ER -